
Early-stage investor turning scientific breakthroughs into industrial companies in energy, materials, mining and agriculture

Technology transfer and venture organisation commercialising life science inventions and biomedical tools

From a life science idea to a patent and then a product, Research Corporation Technologies guides inventors and founders through each step. It describes its purpose as creating partnerships that change medicine, and it translates next-generation life science inventions from concept to patent and from patent to product. Its focus is biotechnology and medical devices, and it describes its role as offering biomedical innovators the experience, expertise and funding that success requires. It is connected to the Frederick Gardner Cottrell Foundation.
The company licenses new and promising biomedical technologies and products to industry. Its list of technologies includes the CH2 domain scaffold known as ABDURINS, an endotoxin-free ClearColi expression system, a fibronectin artificial antibody scaffold, a granulocyte-macrophage colony stimulating factor, the Pichia classic expression platform, the GlyoSwitch protein expression system, ultrasound tissue harmonic imaging, and lacosamide, sold as VIMPAT, for the treatment of epileptic seizures.
Through its RCT Ventures program, the company provides venture capital to start-up and early-stage companies whose technologies could become significant biomedical products with a clear competitive edge. It also develops and invests in technologies that help discover and manufacture therapeutics and diagnostics, and many of these life science tools are available under nonexclusive licenses.
Protein expression systems are a core part of what the company offers. In 2015 it announced, together with AdvaMed, that the finals of the MedTech Innovator competition would take place at AdvaMed's 2015 event. Its news feed also reports that AustinPx's KinetiSol technology received an advanced manufacturing technology designation from the US Food and Drug Administration's drug evaluation center.
Research Corporation Technologies works with inventors and founders to turn life science ideas into patents and then into commercial products. Its focus is biotechnology and medical devices.
Entrepreneurs, inventors and biomedical companies. It also co-hosted the 2015 MedTech Innovator finals with AdvaMed.
Summary written by TrustList from the business's own published information, Nov 2026.
2 images - click to enlarge
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about Research Corporation Technologies.
Similar listings buyers compare against this one.

Early-stage investor turning scientific breakthroughs into industrial companies in energy, materials, mining and agriculture

Seed-stage investor in technology companies addressing social and environmental needs, from New York and Boston

Venture investing arm of Johnson & Johnson Innovation, supporting life science innovation

Private equity fund of CLSA investing in Belt and Road opportunities across consumer, technology, media and infrastructure

Austin-based evergreen venture firm investing in software, technology-enabled and life science companies

Entrepreneur-led Australian venture capital firm providing Series A funding to high-growth technology startups

India and Japan startup accelerator helping Indian ventures prepare for funding and international expansion

Corporate venture arm of Dell investing in early-stage enterprise technology companies
Everything here links back to the same verified catalogue. Pick your next stop.